Comparing Cerus (CERS) and Its Competitors
Cerus (NASDAQ: CERS) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it contrast to its competitors? We will compare Cerus to similar companies based on the strength of its institutional ownership, risk, valuation, profitability, analyst recommendations, dividends and earnings.
Volatility and Risk
Cerus has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Cerus’ competitors have a beta of 0.36, indicating that their average share price is 64% less volatile than the S&P 500.
This table compares Cerus and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cerus||$39.28 million||-$62.90 million||-6.59|
|Cerus Competitors||$1.67 billion||$207.58 million||55.89|
Cerus’ competitors have higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Cerus and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
58.5% of Cerus shares are owned by institutional investors. Comparatively, 54.9% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 7.4% of Cerus shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings for Cerus and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cerus presently has a consensus price target of $7.00, indicating a potential upside of 79.95%. As a group, “Medical Devices & Implants” companies have a potential upside of 37.75%. Given Cerus’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cerus is more favorable than its competitors.
Cerus competitors beat Cerus on 7 of the 12 factors compared.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.